Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of...
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease...
View ArticleSorafenib stops tumor growth, provides effective treatment for thyroid cancer...
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented...
View ArticleStudy provides important details for recently identified target in lung...
In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene...
View ArticleBayer, Onyx submit sNDA to FDA, marketing authorization application to EMA...
Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization...
View ArticleFDA grants Priority Review designation to sNDA for Nexavar tablets
Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral...
View ArticleAntioxidant substances in red wine, dark chocolate, olive oil linked with...
The scientific spotlight focuses today on the healthful antioxidant substances in red wine, dark chocolate, olive oil, coffee, tea, and other foods and dietary supplements that are enticing millions of...
View ArticleDiscoveries pave way for use of new therapies for advanced thyroid cancer
For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of...
View ArticleNew drug combination therapy effectively kills cancer cells
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung,...
View ArticleNEXAVAR tablets receive FDA approval for treatment of patients with thyroid...
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral...
View ArticleNovartis to present updates on broad cancer portfolio at ASH and SABCS...
Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer...
View ArticleVG Life Sciences provides update to HCQ-sorafenib combination Phase I Study...
VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage...
View ArticleHopkins scientists design new mouse that mimics common form of leukemia
Johns Hopkins Kimmel Cancer Center investigators have genetically engineered a new mouse that mimics a common form of leukemia in humans. Studying the model could lead to new understanding of the...
View ArticleResearchers identify potential genes that can be targeted for new treatments...
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of...
View ArticlePfizer and Merck join forces to explore therapeutic potential of anti-PD-1...
Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic...
View ArticleBayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients...
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib)...
View ArticleResearchers identify experimental drugs to block treatment-resistant leukemia
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for...
View ArticleAdoptive T-cell therapy may help in treating liver cancer, says study
Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.
View ArticleMultiple lines of targeted therapy extend life for mRCC patients
Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database.
View ArticleCombination treatments for unresectable and metastatic melanomas: an...
Melanoma is the most serious and deadly form of skin cancer. Unresectable melanoma is melanoma that has spread locally and cannot be removed by surgery, while metastatic melanoma is melanoma that has...
View ArticleFDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for...
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the...
View Article
